Avalyn Pharma Inc. (NASDAQ:AVLN – Get Free Report) insider Howard Lazarus sold 13,300 shares of the business’s stock in a transaction that occurred on Tuesday, November 17th. The stock was sold at an average price of $27.90, for a total value of $371,070.00. Following the completion of the transaction, the insider owned 13,300 shares in the company, valued at $371,070. The trade was a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Avalyn Pharma Price Performance
AVLN stock opened at $28.40 on Friday. The company has a quick ratio of 25.76, a current ratio of 25.76 and a debt-to-equity ratio of 0.04. The business has a 50 day moving average of $27.93 and a 200-day moving average of $29.87. Avalyn Pharma Inc. has a 12-month low of $22.24 and a 12-month high of $40.17.
Avalyn Pharma (NASDAQ:AVLN – Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.03). On average, sell-side analysts predict that Avalyn Pharma Inc. will post -3.87 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Avalyn Pharma
Several large investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. bought a new stake in shares of Avalyn Pharma in the 3rd quarter worth approximately $29,000. Manchester Capital Management LLC purchased a new position in Avalyn Pharma in the third quarter valued at approximately $36,000. Algert Global LLC bought a new position in Avalyn Pharma during the third quarter valued at $465,000. Profund Advisors LLC bought a new position in Avalyn Pharma during the third quarter valued at $668,000. Finally, Bank of New York Mellon Corp bought a new position in Avalyn Pharma during the second quarter valued at $1,321,000.
Analysts Set New Price Targets
Several brokerages have recently issued reports on AVLN. Morgan Stanley decreased their target price on Avalyn Pharma from $57.00 to $53.00 and set an “overweight” rating for the company in a research report on Monday, November 16th. Weiss Ratings reissued a “sell (d+)” rating on shares of Avalyn Pharma in a report on Wednesday, November 11th. Raymond James Financial assumed coverage on shares of Avalyn Pharma in a report on Friday, October 2nd. They issued an “outperform” rating and a $60.00 price target on the stock. Finally, Wall Street Zen upgraded shares of Avalyn Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, November 14th. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Avalyn Pharma has a consensus rating of “Moderate Buy” and a consensus target price of $59.20.
Avalyn Pharma Company Profile
Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled treatments for pulmonary fibrosis, including idiopathic pulmonary fibrosis and other progressive fibrotic lung diseases. Its approach is designed to deliver medicine directly to the lungs. The company’s pipeline includes AP01, an investigational inhaled formulation of pirfenidone, and AP02, an investigational inhaled formulation of nintedanib. Both medicines are based on drugs used in oral form for pulmonary fibrosis, but Avalyn’s inhaled candidates are being studied as potential alternatives to oral treatment.
Recommended Stories
- Five stocks we like better than Avalyn Pharma
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Avalyn Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalyn Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
